<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='110'><Row><Action id="2659">Cardioprotectant</Action><AuthorityGroup/><Company id="1010999">Takara Bio Europe Ab</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="DK">Denmark</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="30651">Takara Holdings Inc</ParentCompany><Patent id="PA2917454">WO-2004099394</Patent><Status id="PRI">First Priority</Status><StatusDate>2003-05-08 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="2659">Cardioprotectant</Action><AuthorityGroup/><Company id="1010999">Takara Bio Europe Ab</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="30651">Takara Holdings Inc</ParentCompany><Patent id="PA2917454">WO-2004099394</Patent><Status id="PRI">First Priority</Status><StatusDate>2003-05-08 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="2659">Cardioprotectant</Action><AuthorityGroup/><Company id="1010999">Takara Bio Europe Ab</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="30651">Takara Holdings Inc</ParentCompany><Patent id="PA2917454">WO-2004099394</Patent><Status id="PUB">First Publication</Status><StatusDate>2004-11-18 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="184">Alpha-glucosidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="184">Alpha-glucosidase inhibitor</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="184">Alpha-glucosidase inhibitor</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7162">Glucosylceramidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7162">Glucosylceramidase inhibitor</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7162">Glucosylceramidase inhibitor</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7211">CNS diagnostic agent</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7211">CNS diagnostic agent</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7211">CNS diagnostic agent</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7214">Genetic diagnostic agent</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7214">Genetic diagnostic agent</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7214">Genetic diagnostic agent</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PRI">First Priority</Status><StatusDate>2004-05-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="184">Alpha-glucosidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="184">Alpha-glucosidase inhibitor</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="184">Alpha-glucosidase inhibitor</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7162">Glucosylceramidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7162">Glucosylceramidase inhibitor</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7162">Glucosylceramidase inhibitor</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7211">CNS diagnostic agent</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7211">CNS diagnostic agent</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7211">CNS diagnostic agent</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7214">Genetic diagnostic agent</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7214">Genetic diagnostic agent</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7214">Genetic diagnostic agent</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="PUB">First Publication</Status><StatusDate>2006-01-12 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="184">Alpha-glucosidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="184">Alpha-glucosidase inhibitor</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="184">Alpha-glucosidase inhibitor</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7162">Glucosylceramidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7162">Glucosylceramidase inhibitor</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7162">Glucosylceramidase inhibitor</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7211">CNS diagnostic agent</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7211">CNS diagnostic agent</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7211">CNS diagnostic agent</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7214">Genetic diagnostic agent</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7214">Genetic diagnostic agent</Action><AuthorityGroup/><Company id="20525">University of Alberta</Company><CompanyOwnershipRelationship>Third Party</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="20525">University of Alberta</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7214">Genetic diagnostic agent</Action><AuthorityGroup/><Company id="21238">McMaster University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="13513">probucol</Drug><DrugRelationship>General interest</DrugRelationship><EntityType/><HighestPatStatus id="GRT">Granted</HighestPatStatus><HighestPatStatusForCnty>Granted</HighestPatStatusForCnty><HighestPatStatusIdForCnty>GRT</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21238">McMaster University</ParentCompany><Patent id="PA3074149">US-07488721</Patent><Status id="GRT">Granted</Status><StatusDate>2009-02-10 00:00:00</StatusDate><StatusSortCode>3</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="10443">Rab GTPase modulator</Action><AuthorityGroup/><Company id="1016838">FoldRx Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="18767">Pfizer Inc</ParentCompany><Patent id="PA3531567">WO-2007089548</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-01-26 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="1767">Protein synthesis modulator</Action><AuthorityGroup/><Company id="1016838">FoldRx Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="18767">Pfizer Inc</ParentCompany><Patent id="PA3531567">WO-2007089548</Patent><Status id="PRI">First Priority</Status><StatusDate>2006-01-26 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="10443">Rab GTPase modulator</Action><AuthorityGroup/><Company id="1016838">FoldRx Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="18767">Pfizer Inc</ParentCompany><Patent id="PA3531567">WO-2007089548</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-08-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="1767">Protein synthesis modulator</Action><AuthorityGroup/><Company id="1016838">FoldRx Pharmaceuticals Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="18767">Pfizer Inc</ParentCompany><Patent id="PA3531567">WO-2007089548</Patent><Status id="PUB">First Publication</Status><StatusDate>2007-08-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7162">Glucosylceramidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA4628162">WO-2009049421</Patent><Status id="PRI">First Priority</Status><StatusDate>2007-10-18 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7162">Glucosylceramidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA4628162">WO-2009049421</Patent><Status id="PUB">First Publication</Status><StatusDate>2009-04-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="18440">Alpha-L-iduronidase modulator</Action><AuthorityGroup/><Company id="25861">BioMarin Pharmaceutical Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="38270">elosulfase alfa</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Patent id="PA5324622">WO-2009091994</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-01-18 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="60172">N-acetylgalactosamine 6 sulfatase stimulator</Action><AuthorityGroup/><Company id="25861">BioMarin Pharmaceutical Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="38270">elosulfase alfa</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Patent id="PA5324622">WO-2009091994</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-01-18 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7214">Genetic diagnostic agent</Action><AuthorityGroup/><Company id="25861">BioMarin Pharmaceutical Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="38270">elosulfase alfa</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Patent id="PA5324622">WO-2009091994</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-01-18 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9223">Sulfatase stimulator</Action><AuthorityGroup/><Company id="25861">BioMarin Pharmaceutical Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="38270">elosulfase alfa</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Patent id="PA5324622">WO-2009091994</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-01-18 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="18440">Alpha-L-iduronidase modulator</Action><AuthorityGroup/><Company id="25861">BioMarin Pharmaceutical Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="38270">elosulfase alfa</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Patent id="PA5324622">WO-2009091994</Patent><Status id="PUB">First Publication</Status><StatusDate>2009-07-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="60172">N-acetylgalactosamine 6 sulfatase stimulator</Action><AuthorityGroup/><Company id="25861">BioMarin Pharmaceutical Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="38270">elosulfase alfa</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Patent id="PA5324622">WO-2009091994</Patent><Status id="PUB">First Publication</Status><StatusDate>2009-07-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7214">Genetic diagnostic agent</Action><AuthorityGroup/><Company id="25861">BioMarin Pharmaceutical Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="38270">elosulfase alfa</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Patent id="PA5324622">WO-2009091994</Patent><Status id="PUB">First Publication</Status><StatusDate>2009-07-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9223">Sulfatase stimulator</Action><AuthorityGroup/><Company id="25861">BioMarin Pharmaceutical Inc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="38270">elosulfase alfa</Drug><DrugRelationship>Process</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25861">BioMarin Pharmaceutical Inc</ParentCompany><Patent id="PA5324622">WO-2009091994</Patent><Status id="PUB">First Publication</Status><StatusDate>2009-07-23 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="186">Beta-glucosidase inhibitor</Action><AuthorityGroup/><Company id="1053857">International University Of Health &amp; Welfare</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="186">Beta-glucosidase inhibitor</Action><AuthorityGroup/><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="186">Beta-glucosidase inhibitor</Action><AuthorityGroup/><Company id="25013">Universidad de Sevilla</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="186">Beta-glucosidase inhibitor</Action><AuthorityGroup/><Company id="25971">Tottori University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25971">Tottori University</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7149">Beta-galactosidase inhibitor</Action><AuthorityGroup/><Company id="1053857">International University Of Health &amp; Welfare</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7149">Beta-galactosidase inhibitor</Action><AuthorityGroup/><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7149">Beta-galactosidase inhibitor</Action><AuthorityGroup/><Company id="25013">Universidad de Sevilla</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7149">Beta-galactosidase inhibitor</Action><AuthorityGroup/><Company id="25971">Tottori University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25971">Tottori University</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9201">Beta-glycosidase stimulator</Action><AuthorityGroup/><Company id="1053857">International University Of Health &amp; Welfare</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9201">Beta-glycosidase stimulator</Action><AuthorityGroup/><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9201">Beta-glycosidase stimulator</Action><AuthorityGroup/><Company id="25013">Universidad de Sevilla</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9201">Beta-glycosidase stimulator</Action><AuthorityGroup/><Company id="25971">Tottori University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="ES">Spain</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25971">Tottori University</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PRI">First Priority</Status><StatusDate>2008-10-22 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="186">Beta-glucosidase inhibitor</Action><AuthorityGroup/><Company id="1053857">International University Of Health &amp; Welfare</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="186">Beta-glucosidase inhibitor</Action><AuthorityGroup/><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="186">Beta-glucosidase inhibitor</Action><AuthorityGroup/><Company id="25013">Universidad de Sevilla</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="186">Beta-glucosidase inhibitor</Action><AuthorityGroup/><Company id="25971">Tottori University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25971">Tottori University</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7149">Beta-galactosidase inhibitor</Action><AuthorityGroup/><Company id="1053857">International University Of Health &amp; Welfare</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7149">Beta-galactosidase inhibitor</Action><AuthorityGroup/><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7149">Beta-galactosidase inhibitor</Action><AuthorityGroup/><Company id="25013">Universidad de Sevilla</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7149">Beta-galactosidase inhibitor</Action><AuthorityGroup/><Company id="25971">Tottori University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25971">Tottori University</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9201">Beta-glycosidase stimulator</Action><AuthorityGroup/><Company id="1053857">International University Of Health &amp; Welfare</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1053857">International University Of Health &amp; Welfare</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9201">Beta-glycosidase stimulator</Action><AuthorityGroup/><Company id="21336">Consejo Superior De Investigaciones Cientificas</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="21336">Consejo Superior De Investigaciones Cientificas</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9201">Beta-glycosidase stimulator</Action><AuthorityGroup/><Company id="25013">Universidad de Sevilla</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25013">Universidad de Sevilla</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="9201">Beta-glycosidase stimulator</Action><AuthorityGroup/><Company id="25971">Tottori University</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="25971">Tottori University</ParentCompany><Patent id="PA5579673">WO-2010046517</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-04-29 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="16836">Acid ceramidase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PRI">First Priority</Status><StatusDate>2009-03-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="18441">Alpha-L-iduronidase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PRI">First Priority</Status><StatusDate>2009-03-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="36308">Galactocerebrosidase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PRI">First Priority</Status><StatusDate>2009-03-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="51969">Sphingomyelin phosphodiesterase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PRI">First Priority</Status><StatusDate>2009-03-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="60172">N-acetylgalactosamine 6 sulfatase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PRI">First Priority</Status><StatusDate>2009-03-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7150">Beta-galactosidase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PRI">First Priority</Status><StatusDate>2009-03-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7170">Beta-N-acetylhexosaminidase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PRI">First Priority</Status><StatusDate>2009-03-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="8578">Alpha-glucosidase 1 stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PRI">First Priority</Status><StatusDate>2009-03-13 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="16836">Acid ceramidase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-09-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="18441">Alpha-L-iduronidase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-09-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="36308">Galactocerebrosidase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-09-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="51969">Sphingomyelin phosphodiesterase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-09-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="60172">N-acetylgalactosamine 6 sulfatase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-09-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7150">Beta-galactosidase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-09-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="7170">Beta-N-acetylhexosaminidase stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-09-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="8578">Alpha-glucosidase 1 stimulator</Action><AuthorityGroup/><Company id="1054868">Bionaturis</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1054868">Bionaturis</ParentCompany><Patent id="PA5717158">WO-2010103137</Patent><Status id="PUB">First Publication</Status><StatusDate>2010-09-16 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA6538814">US-20110195985</Patent><Status id="PRI">First Priority</Status><StatusDate>2010-02-09 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="676">Beta-N-acetylhexosaminidase inhibitor</Action><AuthorityGroup/><Company id="16994">Hospital for Sick Children</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="16994">Hospital for Sick Children</ParentCompany><Patent id="PA6538814">US-20110195985</Patent><Status id="PUB">First Publication</Status><StatusDate>2011-08-11 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="4154">Diagnostic agent</Action><AuthorityGroup/><Company id="1006569">Agency For Science Technology &amp; Research</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="SG">Singapore</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1006569">Agency For Science Technology &amp; Research</ParentCompany><Patent id="PA8229147">US-20150192589</Patent><Status id="PRI">First Priority</Status><StatusDate>2014-01-08 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="4154">Diagnostic agent</Action><AuthorityGroup/><Company id="1006569">Agency For Science Technology &amp; Research</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1006569">Agency For Science Technology &amp; Research</ParentCompany><Patent id="PA8229147">US-20150192589</Patent><Status id="PUB">First Publication</Status><StatusDate>2015-07-09 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="836">Androgen receptor modulator</Action><AuthorityGroup/><Company id="28355">GlaxoSmithKline plc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="US">US</Country><Drug id="89982">GSK-2881078</Drug><DrugRelationship>Product (derivative)</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Patent id="PA8244691">WO-2015110958</Patent><Status id="PRI">First Priority</Status><StatusDate>2014-01-21 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="836">Androgen receptor modulator</Action><AuthorityGroup/><Company id="28355">GlaxoSmithKline plc</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug id="89982">GSK-2881078</Drug><DrugRelationship>Product (derivative)</DrugRelationship><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="28355">GlaxoSmithKline plc</ParentCompany><Patent id="PA8244691">WO-2015110958</Patent><Status id="PUB">First Publication</Status><StatusDate>2015-07-30 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="16841">C-type natriuretic peptide ligand</Action><AuthorityGroup/><Company id="1007879">Ascendis Pharma A/S</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="EP">European Patent</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Priority</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PRI</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1007879">Ascendis Pharma A/S</ParentCompany><Patent id="PA8748861">WO-2016110577</Patent><Status id="PRI">First Priority</Status><StatusDate>2015-01-09 00:00:00</StatusDate><StatusSortCode>1</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row><Row><Action id="16841">C-type natriuretic peptide ligand</Action><AuthorityGroup/><Company id="1007879">Ascendis Pharma A/S</Company><CompanyOwnershipRelationship>Owner</CompanyOwnershipRelationship><Country id="WO">World</Country><Drug/><DrugRelationship/><EntityType/><HighestPatStatus id="PUB">First Publication</HighestPatStatus><HighestPatStatusForCnty>First Publication</HighestPatStatusForCnty><HighestPatStatusIdForCnty>PUB</HighestPatStatusIdForCnty><Indication id="1880">Morquio disease</Indication><LatestChange/><ParentCompany id="1007879">Ascendis Pharma A/S</ParentCompany><Patent id="PA8748861">WO-2016110577</Patent><Status id="PUB">First Publication</Status><StatusDate>2016-07-14 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="57">Cardiovascular disease</TherapyArea></Row></Rowset>